Schrödinger, Inc. (NASDAQ:SDGR) Receives $32.80 Average PT from Analysts

Schrödinger, Inc. (NASDAQ:SDGR) has been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $32.80.

Several research analysts have recently weighed in on the stock. Piper Sandler decreased their price objective on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. KeyCorp increased their price target on Schrödinger from $30.00 to $32.00 and gave the company an “overweight” rating in a report on Wednesday, April 16th.

Schrödinger Trading Down 1.1%

Shares of SDGR opened at $21.20 on Tuesday. Schrödinger has a 12 month low of $16.60 and a 12 month high of $28.47. The business’s fifty day simple moving average is $23.70 and its two-hundred day simple moving average is $22.40. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -9.06 and a beta of 1.63.

Schrödinger (NASDAQ:SDGR) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.01). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The business had revenue of $59.55 million during the quarter, compared to the consensus estimate of $54.60 million. During the same quarter in the previous year, the business posted ($0.86) earnings per share. Schrödinger’s quarterly revenue was up 62.7% compared to the same quarter last year. As a group, research analysts forecast that Schrödinger will post -2.37 EPS for the current year.

Insider Transactions at Schrödinger

In other news, insider Karen Akinsanya sold 16,723 shares of the company’s stock in a transaction on Monday, April 14th. The stock was sold at an average price of $25.09, for a total value of $419,580.07. Following the completion of the sale, the insider now directly owns 15,625 shares in the company, valued at $392,031.25. This represents a 51.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Schrödinger

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC lifted its position in shares of Schrödinger by 421.6% during the 3rd quarter. Barclays PLC now owns 107,554 shares of the company’s stock valued at $1,995,000 after buying an additional 86,933 shares in the last quarter. KBC Group NV raised its stake in Schrödinger by 73.9% during the 4th quarter. KBC Group NV now owns 4,361 shares of the company’s stock worth $84,000 after acquiring an additional 1,853 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its stake in Schrödinger by 60.2% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,510,518 shares of the company’s stock worth $67,718,000 after acquiring an additional 1,319,464 shares during the period. Stephens Investment Management Group LLC lifted its holdings in Schrödinger by 4.4% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,607,656 shares of the company’s stock valued at $31,012,000 after purchasing an additional 67,786 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Schrödinger by 3.1% in the fourth quarter. Principal Financial Group Inc. now owns 270,449 shares of the company’s stock worth $5,217,000 after purchasing an additional 8,138 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.